AI Article Synopsis
- Two unrelated proteins, Omomyc and p31, are engineered as CD44-targeted inclusion bodies in bacteria.
- These inclusion bodies can selectively kill CD44 tumor cells in lab cultures and destroy tumor tissue in mice with breast cancer when administered locally.
- The study suggests that bacterial inclusion bodies could be useful for slowly releasing therapeutic proteins in chronic diseases like cancer.
Article Abstract
Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44 tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755514 | PMC |
| http://dx.doi.org/10.1002/advs.201900849 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!